Kanyrpharma
Kanyr was incorporated in May 2013.
Acquired rights from McGill for two major cancer programs:
PRL-PTP inhibitor and ImmunyrTM technology.
In the process of establishing seed funding.
Kanyr’s research team possesses over 15 years of experience in the PTP field.
Is a “world-leader” in the understanding of how to chemically target PTP gene family.
The PTP gene-family is associated with multiple human diseases but remains one of the few untapped areas of drug discovery.
Unique opportunity
PTPs have long been thought to be “undruggable”. Recent successes show that this is no longer the case.
The PTP inhibitor field is currently at the nascent stage. About the same as kinase inhibitors were 20 years ago. Kinase inhibitors are now a central part of modern medicine.
Kanyr is focused on three broadly applicable anti-cancer programs: PTP Inhibitor Immunotherapy – ImmunyrTM technology and PRL-PTP Inhibitors